Novartis preps Kisqali for FDA; Ventyx cuts 20% of workers; Keytruda plus Lenvima hits PhIII setback

Plus news about Rigel Phar­ma­ceu­ti­cals col­lab­o­rat­ing with MD An­der­son.

No­var­tis up­dates PhI­II da­ta for Kisqali: The com­pa­ny has al­ready filed the NA­TALEE da­ta with the EMA and will sub­mit up­dat­ed da­ta to the FDA by the end of the year. Kisqali is cur­rent­ly ap­proved in the metasta­t­ic dis­ease set­ting.

Ven­tyx slash­es 20% of work­force: The com­pa­ny end­ed Sep­tem­ber with 99 full-time em­ploy­ees and around $56 mil­lion in cash. The move is ex­pect­ed to cost the biotech $2 mil­lion in sev­er­ance and re­lat­ed em­ploy­ee ben­e­fits. In No­vem­ber, the com­pa­ny cut its pso­ri­a­sis pro­gram on the back of lack­lus­ter Phase II re­sults, prompt­ing a steep drop in its share price $VTYX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.